YOLFTbeta
PepGen Ltd

PepGen Ltd

PEPG · NASDAQ · Healthcare / Biotechnology

4.36USD-0.68 (-13.49%)

Price History

Full chart

Market Stats

Previous Close5.04
Open5.08
Day Range4.34 – 5.08
52-Week Range1.31 – 7.80
Volume5.87M
Market Cap179.15M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.00
Dividend Yield0.00%
Beta1.97
50-Day Avg2.69
200-Day Avg3.48

About

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. James G. McArthur Ph.D.
  • Employees57
  • Headquarters321 Harrison Avenue, Boston, MA, United States, 02118, USA
  • Websitehttps://www.pepgen.com

Leadership

  • Dr. James G. McArthur Ph.D.President, CEO, Treasurer, Secretary & Director · b. 1962
  • Mr. Noel P. Donnelly M.B.A.Chief Financial Officer · b. 1970
  • Mr. Joseph D. Vittiglio Esq., J.D.Chief Business & Legal Officer and Secretary · b. 1972
  • Dr. Kasra Kasraian Ph.D.Chief Technical Officer · b. 1967
  • Ms. Emiko BryantSenior Vice President of HR & Administration
  • Dr. Hayley Parker Ph.D.Senior Vice President of Global Regulatory Affairs & Quality
  • Dr. Paul D. Streck M.B.A., M.D.Executive VP and Head of Research & Development · b. 1964
  • Ms. Pallavi Lonkar Ph.D.Vice President & Head of Preclinical
  • Ms. Melissa MichaelsExecutive Director & Head of Regulatory Affairs CMC
  • Mr. Michael ZhaoVice President & Head of Biometrics

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-000000
Cost of Revenue106.00K110.00K178.00K493.00K1.18M1.50M1.40M
Gross Profit-106.00K-110.00K-178.00K-493.00K-1.18M-1.50M-1.40M
Operating Expense1.25M1.77M26.93M67.81M83.58M96.23M92.22M
Operating Income-1.35M-1.88M-27.11M-68.30M-84.77M-97.74M-93.61M
EBITDA-1.25M-1.77M-27.10M-67.81M-77.37M-89.09M-88.21M
Net Income-1.35M-1.89M-27.28M-69.10M-78.63M-89.98M-89.66M
R&D620.00K1.12M23.80M54.08M68.13M76.48M71.04M
Interest Expense08.00K172.00K3.40M---

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.19M10.64M143.64M217.44M143.05M150.88M173.91M
Total Liabilities326.00K868.00K10.55M37.81M34.63M32.26M26.46M
Total Equity3.87M9.77M133.09M179.63M108.42M118.62M147.44M
Cash3.49M9.78M132.90M181.75M80.77M49.42M60.51M
Total Debt---24.53M20.10M18.66M17.00M
Net Debt-3.49M-9.78M-132.90M-157.22M-60.67M-30.76M-43.51M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-885.00K-1.65M-22.60M-59.27M-69.00M-82.37M-81.64M
Investing Cash Flow-29.00K-8.00K-500.00K-3.75M-32.00M-37.67M-15.23M
Financing Cash Flow2.79M7.95M147.66M112.19M-189.00K88.75M107.98M
Capital Expenditure29.00K8.00K500.00K3.75M2.60M497.00K264.00K
Free Cash Flow-914.00K-1.66M-23.10M-63.02M-71.60M-82.87M-81.90M
FCF to OCF103.28%100.48%102.21%106.34%103.77%100.60%100.32%

Earnings

Report DateOct 1, 2021Feb 11, 2022Jun 16, 2022Aug 12, 2022Nov 10, 2022Mar 23, 2023May 11, 2023Aug 8, 2023Nov 8, 2023Mar 6, 2024May 14, 2024Aug 8, 2024Nov 7, 2024Feb 24, 2025May 8, 2025Aug 7, 2025Nov 12, 2025Mar 4, 2026May 7, 2026Aug 6, 2026Nov 11, 2026
EPS Estimate0.000.00-4.61-0.76-1.00-0.87-0.74-0.75-0.80-1.01-0.64-0.68-0.77-0.81-0.75-0.85-0.56-0.39-0.35-0.30-0.27
EPS Actual-0.54-0.36-18.94-1.23-0.79-0.24-0.69-0.82-0.98-0.81-0.63-0.87-0.66-0.68-0.92-0.70-0.52-0.27-0.26-0.26-
Surprise---310.85%-61.84%21.00%72.41%6.76%-9.33%-22.50%19.80%1.56%-27.94%14.29%16.05%-22.67%17.65%7.14%30.77%26.01%13.33%-
Timing--Pre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-market-Pre-marketPre-marketPre-marketAfter-hours-Pre-marketPre-market

Key Statistics & Ratios

Market Cap179.15M
Enterprise Value105.25M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book1.73
EPS-1.00
Book Value1.73
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-74.99M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-75.45%
Return on Assets-39.12%
Shares Outstanding69.17M
Shares Float36.14M
Beta1.97
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 10.19
  • Strong Buy
    3
  • Buy
    1
  • Sell
    1

Ownership Breakdown

Institutions
82.85%
Insiders
0.23%
Retail / Other
16.92%

Top Institutional Holders

  • RA Capital Management, LLC
    20.06M28.97%
  • COMMODORE CAPITAL LP
    4.47M6.46%
  • Viking Global Investors LP
    3.48M5.03%
  • LAURION CAPITAL MANAGEMENT LP
    2.75M3.97%
  • Vivo Capital, LLC
    2.33M3.36%
  • Vanguard Capital Management, LLC
    1.94M2.80%
  • Awm Investment Company Inc
    1.83M2.64%
  • Millennium Management LLC
    1.79M2.58%
  • Kalehua Capital Management LLC
    1.73M2.50%
  • ADAR1 Capital Management LLC
    1.61M2.32%
  • Woodline Partners LP
    1.31M1.89%
  • BlackRock Inc
    1.28M1.84%
  • Morgan Stanley - Brokerage Accounts
    998.99K1.44%
  • GSA Capital Partners LLP
    852.85K1.23%
  • Qube Research & Technologies
    706.47K1.02%
  • Nantahala Capital Management, LLC
    681.16K0.98%
  • Citadel Advisors Llc
    658.38K0.95%
  • MONIMUS CAPITAL MANAGEMENT, LP
    587.69K0.85%
  • Geode Capital Management, LLC
    536.00K0.77%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.41M2.03%